ES2836208T3 - Ciclopirox, ciclopirox olamina o un profármaco de ciclopirox para usar en el tratamiento del cáncer de vejiga - Google Patents

Ciclopirox, ciclopirox olamina o un profármaco de ciclopirox para usar en el tratamiento del cáncer de vejiga Download PDF

Info

Publication number
ES2836208T3
ES2836208T3 ES15859268T ES15859268T ES2836208T3 ES 2836208 T3 ES2836208 T3 ES 2836208T3 ES 15859268 T ES15859268 T ES 15859268T ES 15859268 T ES15859268 T ES 15859268T ES 2836208 T3 ES2836208 T3 ES 2836208T3
Authority
ES
Spain
Prior art keywords
cpx
ciclopirox
pom
aliphatics
bladder cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15859268T
Other languages
English (en)
Spanish (es)
Inventor
Scott J Weir
Shrikant Anant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kansas
Original Assignee
University of Kansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Kansas filed Critical University of Kansas
Application granted granted Critical
Publication of ES2836208T3 publication Critical patent/ES2836208T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES15859268T 2014-11-11 2015-11-10 Ciclopirox, ciclopirox olamina o un profármaco de ciclopirox para usar en el tratamiento del cáncer de vejiga Active ES2836208T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462078069P 2014-11-11 2014-11-11
US201562134747P 2015-03-18 2015-03-18
PCT/US2015/059955 WO2016077346A1 (en) 2014-11-11 2015-11-10 Methods of bladder cancer treatment with ciclopirox, ciclopirox olamine, or a ciclopirox prodrug

Publications (1)

Publication Number Publication Date
ES2836208T3 true ES2836208T3 (es) 2021-06-24

Family

ID=55954945

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15859268T Active ES2836208T3 (es) 2014-11-11 2015-11-10 Ciclopirox, ciclopirox olamina o un profármaco de ciclopirox para usar en el tratamiento del cáncer de vejiga

Country Status (12)

Country Link
US (1) US20170304329A1 (enExample)
EP (1) EP3217980B1 (enExample)
JP (1) JP2017533952A (enExample)
CN (2) CN116687941A (enExample)
DK (1) DK3217980T3 (enExample)
ES (1) ES2836208T3 (enExample)
HR (1) HRP20201893T1 (enExample)
HU (1) HUE052670T2 (enExample)
PL (1) PL3217980T3 (enExample)
PT (1) PT3217980T (enExample)
RS (1) RS61222B1 (enExample)
WO (1) WO2016077346A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11753379B2 (en) 2018-05-30 2023-09-12 Clariant International Ltd Process for forming 2-hydroxypyridine-1-oxide or derivatives thereof
CN113194945B (zh) * 2018-08-23 2024-07-23 佩勒梅德有限公司 环吡酮的抑制hbv核心组装的用途
WO2021078937A1 (en) * 2019-10-25 2021-04-29 Deutsches Krebsforschungszentrum Treatment of stat3 related diseases by iron chelators
EP4193989A1 (en) 2021-12-09 2023-06-14 Atlas Molecular Pharma, S.L. A formulation for an effective oral administration of ciclopirox with no adversal gasterointestinal toxicity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU754965B2 (en) 1997-12-31 2002-11-28 University Of Kansas, The Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
AU2003251875A1 (en) * 2002-07-15 2004-02-02 Combinatorx, Incorporated Combination therapy for the treatment of neoplasms
WO2010048712A1 (en) 2008-10-31 2010-05-06 University Health Network Ciclopirox and cytarabine for the treatment of leukemic disorders
WO2011153197A1 (en) * 2010-06-01 2011-12-08 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
PL2646035T3 (pl) * 2010-12-02 2016-08-31 Univ Kansas Proleki 6-cykloheksylo-1-hydroksy-4-metylopirydyn-2(1h)-onu i ich pochodne

Also Published As

Publication number Publication date
DK3217980T3 (da) 2020-12-07
EP3217980A4 (en) 2018-05-02
RS61222B1 (sr) 2021-01-29
HRP20201893T1 (hr) 2021-02-05
HUE052670T2 (hu) 2021-05-28
US20170304329A1 (en) 2017-10-26
WO2016077346A1 (en) 2016-05-19
CN107206012A (zh) 2017-09-26
JP2017533952A (ja) 2017-11-16
CN116687941A (zh) 2023-09-05
EP3217980B1 (en) 2020-10-14
PL3217980T3 (pl) 2021-03-22
EP3217980A1 (en) 2017-09-20
PT3217980T (pt) 2020-12-11

Similar Documents

Publication Publication Date Title
US10450305B2 (en) LKB1-AMPK activators for therapeutic use in polycystic kidney disease
CN104363913B (zh) Cdk8/cdk19选择性抑制剂及其在癌症的抗转移和化学预防方法中的用途
US8877791B2 (en) Inhibitors of pyruvate kinase and methods of treating disease
US20200199106A1 (en) Compound for inhibiting and degrading tyrosine protein kinase alk
US9545413B2 (en) Methods of forming ciclopirox or derivatives thereof in a subject by administration of prodrug
KR101990214B1 (ko) 표적 특이적 항암 약물전구체
US20200102264A1 (en) Marmelin analogs and methods of use in cancer treatment
EP3217980B1 (en) Ciclopirox, ciclopirox olamine, or a ciclopirox prodrug for use in the treatment of bladder cancer
US20090312324A1 (en) Compositions and Methods Related to RAD51 Inactivation in the Treatment of Neoplastic Diseases, and Especially CML
US10494365B2 (en) Small molecule inhibitor of 3-phosphoglycerate dehydrogenase and uses thereof
CN106995368B (zh) 一种非atp竞争性fgfr1抑制剂及其应用
US20250228950A1 (en) Prodrugs Activated by Reduction in the Cytosol
US10376515B2 (en) Analogs of adenosine monophosphate (AMP) as inhibitors of ubiquitin-like modifier-activating enzyme ATG7
WO2026053244A1 (en) Phosphorus-containing rucaparib as parp inhibitor
CN118593509A (zh) 非戈替尼作为抗三阴性乳腺癌药物bbdi的增敏剂的用途